OCS
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Oculis Holding AG (OCS) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Value (F).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | F (0.5) | C (2.3) | C+ (2.7) | D- (1.0) | C+ (2.6) | D+ (1.8) |
| 2026-11-06 | D- (0.8) | C- (2.0) | C- (2.0) | D- (1.0) | C+ (2.7) | D+ (1.7) |
| 2026-10-30 | D- (0.7) | B- (3.0) | C (2.3) | D (1.3) | C+ (2.7) | C- (2.0) |
| 2026-10-23 | F (0.7) | B- (3.0) | C (2.3) | D (1.3) | C+ (2.6) | C- (2.0) |
| 2026-10-16 | D- (0.8) | B- (3.0) | C (2.3) | D- (1.1) | C+ (2.6) | C- (2.0) |